Jinlong Zhao1, Lingfeng Zeng2, Ming Wu3, Hetao Huang4, Guihong Liang5, Weiyi Yang6, Jianke Pan7, Jun Liu8. 1. The Second School of Clinical Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China; The Research Team on Bone and Joint Degeneration and Injury, Guangdong Provincial Academy of Traditional Chinese Medicine, Guangzhou, 510120, China. Electronic address: zhaojinlong41@163.com. 2. The Second School of Clinical Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China; The Research Team on Bone and Joint Degeneration and Injury, Guangdong Provincial Academy of Traditional Chinese Medicine, Guangzhou, 510120, China. Electronic address: lingfengzeng0202@163.com. 3. The Second School of Clinical Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China; The Research Team on Bone and Joint Degeneration and Injury, Guangdong Provincial Academy of Traditional Chinese Medicine, Guangzhou, 510120, China. Electronic address: 1726249702@qq.com. 4. The Second Affiliated Hospital, Guangzhou University of Chinese Medicine (Guangdong Province Hospital of Traditional Chinese Medicine), Guangzhou, 510120, China; The Research Team on Bone and Joint Degeneration and Injury, Guangdong Provincial Academy of Traditional Chinese Medicine, Guangzhou, 510120, China. Electronic address: ynhtsmile@126.com. 5. The Second Affiliated Hospital, Guangzhou University of Chinese Medicine (Guangdong Province Hospital of Traditional Chinese Medicine), Guangzhou, 510120, China; The Research Team on Bone and Joint Degeneration and Injury, Guangdong Provincial Academy of Traditional Chinese Medicine, Guangzhou, 510120, China. Electronic address: liangguihonghe@163.com. 6. The Second Affiliated Hospital, Guangzhou University of Chinese Medicine (Guangdong Province Hospital of Traditional Chinese Medicine), Guangzhou, 510120, China; The Research Team on Bone and Joint Degeneration and Injury, Guangdong Provincial Academy of Traditional Chinese Medicine, Guangzhou, 510120, China. Electronic address: czyangwy@163.com. 7. The Second Affiliated Hospital, Guangzhou University of Chinese Medicine (Guangdong Province Hospital of Traditional Chinese Medicine), Guangzhou, 510120, China; The Research Team on Bone and Joint Degeneration and Injury, Guangdong Provincial Academy of Traditional Chinese Medicine, Guangzhou, 510120, China. Electronic address: panjianke0324@126.com. 8. The Second Affiliated Hospital, Guangzhou University of Chinese Medicine (Guangdong Province Hospital of Traditional Chinese Medicine), Guangzhou, 510120, China; The Research Team on Bone and Joint Degeneration and Injury, Guangdong Provincial Academy of Traditional Chinese Medicine, Guangzhou, 510120, China. Electronic address: gzucmliujun@foxmail.com.
Abstract
BACKGROUND AND PURPOSE: Chinese patent medicines (CPMs) have gained increasing attention for the treatment of primary osteoporosis (POP), but there is a lack of high-quality evidence regarding their efficacy. We conducted a network meta-analysis that considered both direct and indirect comparisons to assess and rank the efficacy and safety of CPMs for POP. METHODS: Seven electronic databases were searched from their inception to May 2020. A random effects model was applied within a frequentist framework. RESULTS: Thirty-eight studies with 16 kinds of medicines (13 CPMs, 3 Western medicines) and 3,941 patients were included in this study. This study showed that Jintiange capsule was the most efficacious for increasing the L2-L4 average bone mineral density (BMD) and that Zuogui Wan was the most efficacious for increasing the femoral neck BMD. Compared with calcium, Gusongjiangu Wan (RR = 10.04, 95% CI 1.36-74.32, p = 0.008), Gushukang granules (RR = 12.63, 95% CI 2.02-78.99, p = 0.015) and Xianling Gubao capsule (RR = 6.06, 95% CI 1.38-26.65, p = 0.0003) had fewer adverse reactions. CONCLUSION: In the treatment of POP, Jintiange capsule and Zuogui Wan are effective CPMs for improving the BMD of the lumbar spine and femoral neck, respectively.
BACKGROUND AND PURPOSE: Chinese patent medicines (CPMs) have gained increasing attention for the treatment of primary osteoporosis (POP), but there is a lack of high-quality evidence regarding their efficacy. We conducted a network meta-analysis that considered both direct and indirect comparisons to assess and rank the efficacy and safety of CPMs for POP. METHODS: Seven electronic databases were searched from their inception to May 2020. A random effects model was applied within a frequentist framework. RESULTS: Thirty-eight studies with 16 kinds of medicines (13 CPMs, 3 Western medicines) and 3,941 patients were included in this study. This study showed that Jintiange capsule was the most efficacious for increasing the L2-L4 average bone mineral density (BMD) and that Zuogui Wan was the most efficacious for increasing the femoral neck BMD. Compared with calcium, Gusongjiangu Wan (RR = 10.04, 95% CI 1.36-74.32, p = 0.008), Gushukang granules (RR = 12.63, 95% CI 2.02-78.99, p = 0.015) and Xianling Gubao capsule (RR = 6.06, 95% CI 1.38-26.65, p = 0.0003) had fewer adverse reactions. CONCLUSION: In the treatment of POP, Jintiange capsule and Zuogui Wan are effective CPMs for improving the BMD of the lumbar spine and femoral neck, respectively.